Side-by-side Chinese-English

含3-羟基-4-吡啶酮片段的EGFR酪氨酸激酶抑制剂的合成及抗肿瘤活性研究

刘燊1 邵加安2 俞永平1

(1.浙江大学药学院浙江省抗肿瘤重点实验室, 浙江杭州 310058)
(2.浙江理工大学理学院化学系, 浙江杭州 310018)

【摘要】目的设计合成含具备铁离子螯合功能的3-羟基-4-吡啶酮片段的4-芳胺基喹唑啉类衍生物,并评价其体外抑制肿瘤增殖活性。方法4-芳胺基-6-硝基-7-氟喹唑啉与3-苄氧基吡啶-4-酮脂肪醇发生取代反应,再经过硝基还原得到4-芳胺基-6-氨基-7-(3-苄氧基-4-吡啶酮)烷氧基喹唑啉中间体,该中间体与各种酰氯或者酸缩合后再脱去苄基得到目标化合物1~6;4-芳胺基-6-氨基-7-烷氧基喹唑啉与3-苄氧基吡啶-4-酮-1-乙酸经缩合后脱苄基得到目标化合物7~12。采用MTT法,以吉非替尼(gefitinib)为阳性对照药,测定目标化合物对人表皮癌细胞系A431、人肺腺癌细胞系H1975和人宫颈癌细胞系He La的增殖抑制活性。结果与结论合成了12个未见文献报道的新化合物,其结构经1H-NM R、M S谱确证;初步体外生物活性筛选结果显示,该类化合物具有较好的抗肿瘤细胞增殖活性,其中化合物1~4、7~10在人表皮癌A431细胞株上的抗增殖活性与阳性对照吉非替尼相当。

【关键词】 EGFR酪氨酸激酶抑制剂;4-芳胺基喹唑啉;3-羟基-4-吡啶酮;多靶标;抗肿瘤活性;

【DOI】

Design, synthesis and antiproliferative activity evaluation of EGFR inhibitors containing 3-hydroxy-4-pyridinone fragment

LIU Shen1 SHAO Jia-an2 YU Yong-ping1

(1.Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Science, Zhejiang University, Hangzhou, China 310058)
(2.Department of Chemistry, College of Science, Zhejiang Sci-Tech University, Hangzhou, China 310018)

【Abstract】The development of multi-targeted tyrosine kinase inhibitors is of great significance for anti-cancer therapy. Epidermal growth factor receptor (EGFR) signaling pathway plays a crucial role in the apoptosis, proliferation, differentiation, migration and cell cycle of cancer cells. Meanwhile, Fe chelators are effective antitumor agents. By incorporating 3-hydroxy-4-pyridinone fragment (a Fe chelator motif) into the conventional quinazoline scaffold of EGFR inhibitors, 12 compounds which may target multiple drug targets were synthesized. The general procedure for the synthesis of target compounds was described and all of them were characterized by 1H-NMR, MS and melting point. In the tumor cell lines tested, most of the compounds exhibit efficient antiproliferative activity on the human epidermal carcinoma cell A431 (with EGFR overexpression) and HeLa, albeit a moderate inhibition in gefitinib-resistant NSCLC cell H1975 (bearing EGFR[L858R/T790M]).

【Keywords】 EGFR tyrosine kinase inhibitor; 4-anilinoquinazoline; 3-hydroxy-4-pyridinone; multiple-target; antiproliferative activity;

【DOI】

Download this article
    References

    [1] XIA G X, CHEN W T, ZHANG J, et al. A chemical tuned strategy to develop novel irreversible EGFRTK inhibitors with improved safety and pharmacokinetic profiles [J]. J M ed Chem, 2014, 57 (23): 9889–9900.

    [2] THOMAS S M, GRANDIS J R. Pharmacokinetic and pharmacodynamic properties of EGFR inhibitors under clinical investigation[J]. Cancer Treat Rev, 2004, 30 (3): 255–268.

    [3] MOULDER S L, YAKES F M, MUTHUSWAMY S K, et al. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo[J]. Cancer Res, 2001, 61 (24): 8887–8895.

    [4] DANCEY J E, FREIDLIN B. Targeting epidermal growth factor receptor—are we missing the mark?[J]. Lancet, 2003, 362 (9377): 62–64.

    [5] RANSON M. Epidermal growth factor receptor tyrosine kinase inhibitors [J]. Br J Cancer, 2004, 90 (12): 2250–2255.

    [6] KONECNY G E, PEGRAM M D, VENKATESAN N, et al. Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab–treated breast cancer cells [J]. Cancer Res, 2006, 66 (3): 1630–639.

    [7] NOLTING M, SCHNEIDER M T, TREPEL M. Lapatinib recent results [J]. Cancer Res, 2014, 201 (201): 125–143.

    [8] RACHID Z, BRAHIMI F, KATSOULAS A, et al. The combitargeting concept: chemical dissection of the dual targeting properties of a series of “CombiTriazenes” [J]. J M ed Chem, 2003, 46 (20): 4313–4321.

    [9] DOMARKAS J, DUDOUIT F, WILLIAMS C, et al. The combitargeting concept: synthesis of stable nitrosoureas designed to inhibit the epidermal growth factor receptor (EGFR) [J]. J M ed Chem, 2006, 49 (12): 3544–3552.

    [10] CAI X, ZHAI H X, FORRESTER J, et al. Discovery of 7-(4- (3-ethylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide (CUDC-101) as a potent multi-acting HDAC, EGFR, and HER2 inhibitor for the treatment of cancer [J]. J M ed Chem, 2010, 53 (5): 2000–2009.

    [11] MAHBOOBI S, SELLMER A, WINKLER M, et al. Novel chimeric histone deacetylase inhibitors: a series of lapatinib hybrides as potent inhibitors of epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2), and histone deacetylase activity [J]. J Med Chem, 2010, 53 (24): 8546–8555.

    [12] YU Y, KOVACEVIC Z, RICHARDSON D R. Tuning cell cycle regulation with an iron key [J]. Cell Cycle, 2007, 6 (16): 1982–1994.

    [13] DARIUS J R, THOMAS M M, SHAFIE N H, et al. Expanding horizons in iron chelation and the treatment of cancer: role of iron in the regulation of ER stress and the epithelial-mesenchymal transition [J]. Biochim Biophys Acta, 2014, 1845 (2): 166–181.

    [14] YU Y, DANUTA S, KALINOWS K, et al. Thiosemicarbazones from the old to new: iron chelators that are more than just ribonucleotide reductase inhibitors [J]. J Med Chem, 2009, 52 (17): 5271–5294.

This Article

ISSN:1005-0108

CN:21-1313/R

Vol 27, No. 01, Pages 1-7

February 2017

Downloads:51

Share
Article Outline

Abstract

  • 1 Design of target compounds and synthetic routes
  • 2 Synthetic experiments
  • 3 Antiproliferative activity assay in vitro
  • References